Mads Daugaard

Dr. Mads Daugaard is Head of the Molecular Pathology and Cell Imaging Unit, Senior Research Scientist at Vancouver Prostate Centre (VPC), and associate Professor at Department of Urologic Sciences, University of British Columbia (UBC). Daugaard operates in the translational cancer research space, integrating basic cancer discovery research with experimental therapeutic and diagnostic development in high-risk adult and childhood solid tumors. As part of his translational research focus, Daugaard has established the therapeutic development companies VAR2 Pharmaceuticals and OncoMal (2012), and the cancer diagnostics company VARCT Diagnostics (2017) to facilitate translation of his research towards the clinical arena. He is a co-PI of the VPC small-molecule drug development pipeline ADDUCT. Daugaard has attracted > $10M in federal and foundation support for his academic research programs and secured investments of >$10M for commercial development and translation of his research discoveries. He received the 2019 Robert J. Arceci Innovation Award from the St. Baldrick’s Foundation in 2019 and the Prostate Cancer Canada Rising Star Award in 2014.